Finanzen von Zynex Inc (ZYXI)ZYXIZynex Inc

Zynex Inc (ZYXI) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Zynex Medical, accounting for 98.0% of total sales, equivalent to $3.10M. Another important revenue stream is Zynex NeuroDiagnostics. Understanding this composition is critical for investors evaluating how ZYXI navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Zynex Inc maintains a gross margin of 60.47%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -98.97%, while the net margin is -321.21%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively ZYXI converts its operational activities into shareholder value.

In the context of the broader market, ZYXI competes directly with industry leaders such as ICU and PAVM. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, ZYXI's gross margin of 60.47% stands against ICU's 91.22% and PAVM's -269.70%. Such benchmarking helps identify whether Zynex Inc is trading at a premium or discount relative to its financial performance.